Resources from the same session
912MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Presenter: Li Zhang
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
913MO - Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG
Presenter: James Chow
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
914MO - Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
Presenter: Christian Borel
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
915MO - Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Richard Greil
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
916MO - Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)
Presenter: Charu Aggarwal
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
917MO - TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis
Presenter: Caroline Even
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
918MO - Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
919MO - ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Presenter: Renata Ferrarotto
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Laura Locati
Session: Mini Oral - Head & neck cancer
Resources:
Slides
Invited Discussant 912MO, 913MO and 914MO
Presenter: Pierre Blanchard
Session: Mini Oral - Head & neck cancer
Resources:
Slides
Webcast